Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma HENT1 positive: back to the future

被引：0
|
作者：
Calegari, M. A. [1 ]
Orlandi, A. [1 ]
Cocomazzi, A. [2 ]
Martini, M. [2 ]
Bagala, C. [1 ]
Indellicati, G. [1 ]
Zurlo, V. [1 ]
Monterisi, S. [1 ]
Di Dio, C. [1 ]
Barile, R. [1 ]
Di Salvatore, M. A. [1 ]
Basso, M. [1 ]
Cassano, A. [1 ]
Larocca, L. M. [2 ]
Barone, C. [3 ]
机构：
[1] Univ Cattolica Sacro Cuore, Oncol Med, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Anat Patol, Rome, Italy
[3] Univ Cattolica Sacro Cuore, Med Oncol, I-00168 Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv233.164
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-164
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Gemcitabine versus FOLFIRINOX in patients with advanced hENT1+ve pancreatic adenocarcinoma.
    Calegari, Maria Alessandra
    Orlandi, Armando
    Indellicati, Giulia
    Martini, Maurizio
    Cocomazzi, Alessandra
    Bagala, Cinzia
    Zurlo, Valeria
    Di Dio, Carmela
    Barile, Rosalba
    Monterisi, Santa
    Cassano, Alessandra
    Astone, Antonio
    Barone, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse
    Orlandi, A.
    Calegari, M. A.
    Martini, M.
    Cocomazzi, A.
    Bagala, C.
    Indellicati, G.
    Zurlo, V.
    Basso, M.
    Cassano, A.
    Larocca, L. M.
    Barone, C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (10): : 988 - 995
  • [3] Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse
    A. Orlandi
    M. A. Calegari
    M. Martini
    A. Cocomazzi
    C. Bagalà
    G. Indellicati
    V. Zurlo
    M. Basso
    A. Cassano
    L. M. Larocca
    C. Barone
    Clinical and Translational Oncology, 2016, 18 : 988 - 995
  • [4] hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma
    Perera, Sheron
    Jang, Gun Ho
    Wang, Yifan
    Kelly, Deirdre
    Allen, Michael
    Zhang, Amy
    Denroche, Robert E.
    Dodd, Anna
    Ramotar, Stephanie
    Hutchinson, Shawn
    Tehfe, Mustapha
    Ramjeesingh, Ravi
    Biagi, James
    Lam, Bernard
    Wilson, Julie
    Fischer, Sandra E.
    Zogopoulos, George
    Notta, Faiyaz
    Gallinger, Steven
    Grant, Robert C.
    Knox, Jennifer J.
    O'Kane, Grainne M.
    CLINICAL CANCER RESEARCH, 2022, 28 (23) : 5115 - 5120
  • [5] The hENT1 Immunohistochemistry Diagnostic Test is Predictive of Gemcitabine Outcome in Pancreatic Ductal Adenocarcinoma
    Raponi, Mitch
    Isaacson, Jeff
    Hahn, Hejin
    Bartosiewicz, Mike
    Magnusson, Andrea
    Lin, Kevin
    Rolfe, Lindsey
    Allen, Andrew
    Picozzi, Vincent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S84 - S85
  • [6] THE HENT1 IMMUNOHISTOCHEMISTRY DIAGNOSTIC TEST IS PREDICTIVE OF GEMCITABINE OUTCOME IN PANCREATIC DUCTAL ADENOCARCINOMA
    Raponi, M.
    Isaacson, J.
    Hahn, H.
    Bartosiewicz, M.
    Magnusson, A.
    Lin, K.
    Rolfe, L.
    Allen, A.
    Picozzi, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 236 - 236
  • [7] hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
    Raffenne, Jerome
    Nicolle, Remy
    Puleo, Francesco
    Le Corre, Delphine
    Boyez, Camille
    Marechal, Raphael
    Emile, Jean Francois
    Demetter, Peter
    Bardier, Armelle
    Laurent-Puig, Pierre
    de Mestier, Louis
    Paradis, Valerie
    Couvelard, Anne
    VanLathem, Jean Luc
    MacKey, John R.
    Bachet, Jean-Baptiste
    Svrcek, Magali
    Cros, Jerome
    CANCERS, 2019, 11 (11)
  • [8] hENT1 testing in pancreatic ductal adenocarcinoma: Are we ready yet? A multimodal evaluation of hENT1 status
    Cros, J.
    Marechal, R.
    Bachet, J. B.
    Puleo, F.
    Laurent-Puig, P.
    Bedossa, P.
    Flejou, J. F.
    Demetter, P.
    Svrcek, M.
    VIRCHOWS ARCHIV, 2015, 467 : S7 - S7
  • [9] The association of epithelial expression of hENT1 and survival from adjuvant gemcitabine in pancreatic ductal adenocarcinoma (PDAC).
    Renouf, Daniel John
    Karasinska, Joanna
    Kalloger, Steve
    Samimi, Setareh
    Peixoto, Renata
    O'Connor, Kate
    Schaeffer, David
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] The association of epithelial expression of hENT1 and survival from adjuvant gemcitabine in pancreatic ductal adenocarcinoma (PDAC)
    Renouf, Daniel John
    Karasinska, Joanna
    Kalloger, Steve
    Peixoto, Renata D'Alpino
    O'Connor, Kate
    Schaeffer, David
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345